Resources

Publications

Filter Publications

Product



Year

September 2025

Cholate clearance: improving the assessment of liver health compared to current liver tests (LFTs)

James R. Burton, Jr., MD, Edward Mena, MD, Bhaktasharan Patel, MD | Gastro Hep Advances | September 2025

Current liver function tests (LFTs) either indicate late-stage disease or hepatobiliary injury but do not accurately measure liver function. True quantitative liver function tests, analogous to creatinine clearance for the kidneys, are needed for assessing liver health. read more →

HepQuant DuO

August 2025

The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child Pugh A Cirrhosis

Naim Alkhouri, Michael P. McRae, Rebecca Taub, Brandon Hill, Joanne C. Imperial, John Kittelson, Sam E. Moussa, Gregory T. Everson | Gastro Hep Advances | August 2025

In this study of MASH-related Child-Pugh A cirrhosis (MASH cirrhosis), we used the cholate challenge test to quantify baseline disease severity and the subsequent impact of resmetirom treatment. read more →

HepQuant DuO

April 2025

Assessment of the performance of a dual-sample oral cholate challenge test: The HepQuant DuO test

Michael P. McRae, Touraj Shokati, Uwe Christians, Steve M. Helmke, Gregory T. Everson | Clinica Chimica Acta | April 2025

Liver health is currently evaluated using nonspecific blood tests, fibrosis surrogates, and invasive procedures, none of which directly measure liver function and physiology. The validated HepQuant SHUNT test quantifies liver function and physiology and is linked to clinical outcomes. Herein we present the reliability of a simplified version, the dual-sample oral cholate challenge (HepQuant DuO) test. read more →

HepQuant DuO

March 2025

Letter to the Editor: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy

Tarek Hassanein, Andrew P. Keaveny, Parvez Mantry, Mitchell Shiffman, Michael Leise, Kamran Qureshi, Alastair D. Smith, Michael P. McRae, Joanne C. Imperial, Gregory T. Everson, the SHUNT-V Investigators | Alimentary Pharmacology & Therapeutics| March 2025

HepQuant DuO, HepQuant SHUNT

Alterations in Liver Perfusion in Adults with Fontan Circulation as Assessed by Dual Cholate Clearance

Yuli Y. Kim, Annique Nyman, Yuan-Shung Huang, Alexis Z. Tomlinson, Michael P. McRae, Greg T. Everson, Sumeet Vaikunth, Benjamin Rosenthal, Jack Rychik, Maarouf A. Hoteit | Journal of the American Heart Association | 2025 | March 2025

HepQuant SHUNT

Scientific Research: Posters & Presentations

The Quantitative HepQuant DuO Test Uncovers the Functional Heterogeneity of Advanced Chronic Liver Disease

Author: J.C. Imperial, M.P. McRae, and G.T. Everson

Event: 9th Annual MASH Drug Development Summit

Simultaneous quantification of function of native human liver and porcine liver in an extracorporeal circuit derived from the blood concentrations of intravenously injected 13C-cholate

Author: Abraham Shaked, Michael P. McRae, Joanne C. Imperial, Leanne Lanieri, Alexander Sagar, Kathryn C. Stiede, Kirsten G. Swenson, Peter Friend, Gregory T. Everson

Event: DDW 2025 Presentation

Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO), Hepatic Fibrosis (FibroScan), and Splenic Congestion (Platelet Count) for Accurate Prediction of Portal Hypertension and Clinically Significant Portal Hypertension

Author: J.C. Imperial, M.P. McRae, and G.T. Everson

Event: Liver Connect | March 2025

Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model

Author: J.C. Imperial, M.P. McRae, R. Taub, and G.T. Everson

Event: Liver Connect | March 2025

Quantifying Liver Function by Cholate Clearance in Extracorporeal Circuits with a Genetically Modified Porcine Liver and Brain-Dead Human Decedent

Author: A. Shaked, M.P. McRae, L. Lanieri, A. Sagar, K.C. Stiede, K.G. Swenson, P. Friend, G.T. Everson

Event: EASL May 2025

Poster of Distinction: The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population 

Maintenance Therapy with GLP-1 Receptor Agonists Does Not Impact the​ Clearance of Orally Administered Isotopes of Unconjugated Cholate

Cost-Effectiveness of the HepQuant DuO Test for the Management of Patients at Risk for Large Esophageal Varices

Poster of Distinction: Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO) 

Poster of Distinction: Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model  

The Oral Cholate Challenge Test Identifies the MASH Patients with ≥F3 Fibrosis with Greatest Hepatic Impairment Who Show the Most Benefit from Short-term Rencofilstat Therapy

SEE ALL